



OPEN ACCESS

Edited by:

Mirjam van der Burg,
Leiden University Medical Center,
Netherlands

Reviewed by:

Capucine Picard,
Necker-Enfants Malades Hospital,
France
Bodo Grimbacher,
University Medical Center Freiburg,
Germany

***Correspondence:**

Alessandro Aiuti
aiuti.alessandro@hsr.it
Caterina Cancrini
cancrini@med.uniroma2.it

† These authors have contributed
equally to this work

‡ These authors shared last authorship

Specialty section:

This article was submitted to
Primary Immunodeficiencies,
a section of the journal
Frontiers in Immunology

Received: 08 October 2018

Accepted: 06 February 2019

Published: 11 April 2019

Citation:

Cifaldi C, Brigida I, Barzaghi F, Zoccolillo M, Ferradini V, Petricone D, Cicalese MP, Lazarevic D, Cittaro D, Omrani M, Attardi E, Conti F, Scarselli A, Chiriaco M, Di Cesare S, Licciardi F, Davide M, Ferrua F, Canessa C, Pignata C, Gillani S, Ferrari S, Foustieri G, Barera G, Merli P, Palma P, Cesaro S, Gattorno M, Trizzino A, Moschese V, Chini L, Villa A, Azzari C, Finocchi A, Locatelli F, Rossi P, Sangiuolo F, Aiuti A, Cancrini C and Di Matteo G (2019) Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies. *Front. Immunol.* 10:316. doi: 10.3389/fimmu.2019.00316

Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies

Cristina Cifaldi^{1†}, Immacolata Brigida^{2†}, Federica Barzaghi^{2,3,4†}, Matteo Zoccolillo^{2,4}, Valentina Ferradini⁵, Davide Petricone⁴, Maria Pia Cicalese^{2,3,6}, Dejan Lazarevic⁷, Davide Cittaro⁷, Maryam Omrani², Enrico Attardi¹, Francesca Conti¹, Alessia Scarselli¹, Maria Chiriaco¹, Silvia Di Cesare¹, Francesco Licciardi⁸, Montin Davide⁸, Francesca Ferrua^{2,3,6}, Clementina Canessa^{9,10}, Claudio Pignata¹¹, Silvia Gillani¹², Simona Ferrari¹³, Georgia Foustieri¹⁴, Graziano Barera¹⁵, Pietro Merli¹⁶, Paolo Palma¹, Simone Cesaro¹⁷, Marco Gattorno¹⁸, Antonio Trizzino¹⁹, Viviana Moschese^{4,20}, Loredana Chini^{4,20}, Anna Villa^{21,22}, Chiara Azzari^{9,10}, Andrea Finocchi^{1,4}, Franco Locatelli²³, Paolo Rossi^{1,4}, Federica Sangiuolo⁵, Alessandro Aiuti^{2,3,6*‡}, Caterina Cancrini^{1,4*‡} and Gigliola Di Matteo^{1,4‡}

¹ Unit of Immune and Infectious Diseases, University Department of Pediatrics (DPUO), Scientific Institute for Research and Healthcare (IRCCS) Children's Hospital Bambino Gesù, Rome, Italy, ² San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy, ³ Pediatric Immunohematology and Bone Marrow Transplantation Unit, Scientific Institute for Research and Healthcare (IRCCS) San Raffaele Scientific Institute, Milan, Italy, ⁴ Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, ⁵ Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy, ⁶ Vita Salute San Raffaele University, Milan, Italy, ⁷ Center for Translational Genomics and Bioinformatics, San Raffaele Scientific Institute, Milan, Italy, ⁸ Division of Immunology and Rheumatology, Department of Paediatric Infectious Diseases, Regina Margherita Children's Hospital, University of Turin, Turin, Italy, ⁹ Pediatric Immunology, Department of Health Sciences, University of Florence, Florence, Italy, ¹⁰ Meyer Children's Hospital, Florence, Italy, ¹¹ Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy, ¹² Department of Molecular and Translational Medicine, A. Nocivelli Institute for Molecular Medicine, University of Brescia, Brescia, Italy, ¹³ Unit of Medical Genetics, St. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy, ¹⁴ Division of Immunology Transplantation and Infectious Diseases (DITID), Diabetes Research Institute (DRI) IRCCS San Raffaele Scientific Institute, Milan, Italy, ¹⁵ Pediatric Department, San Raffaele Scientific Institute, Milan, Italy, ¹⁶ Department of Onco-Hematology and Cell and Gene Therapy, Scientific Institute for Research and Healthcare (IRCCS) Children's Hospital Bambino Gesù, Rome, Italy, ¹⁷ Paediatric Hematology-Oncology, "Ospedale della Donna e del Bambino", Verona, Italy, ¹⁸ Pediatric and Rheumatology Unit, Giannina Gaslini Institute, Genoa, Italy, ¹⁹ Department of Pediatric Hematology and Oncology, "ARNAS Civico Di Cristina Benfratelli" Hospital, Palermo, Italy, ²⁰ Pediatric Immunopathology and Allergology Unit, University of Rome Tor Vergata Policlinico Tor Vergata, Rome, Italy, ²¹ Milan Unit, National Research Council (CNR) Institute for Genetic and Biomedical Research (IRGB), Milan, Italy, ²² Humanitas Clinical and Research Institute, Rozzano, Italy, ²³ Department of Pediatric Hematology and Oncology, Scientific Institute for Research and Healthcare (IRCCS) Children's Hospital Bambino Gesù, University of Rome La Sapienza, Rome, Italy

Background: Primary Immunodeficiencies (PIDs) are a heterogeneous group of genetic immune disorders. While some PIDs can manifest with more than one phenotype, signs, and symptoms of various PIDs overlap considerably. Recently, novel defects in immune-related genes and additional variants in previously reported genes responsible for PIDs have been successfully identified by Next Generation Sequencing (NGS), allowing the recognition of a broad spectrum of disorders.

Objective: To evaluate the strength and weakness of targeted NGS sequencing using custom-made Ion Torrent and Haloplex (Agilent) panels for diagnostics and research purposes.

Methods: Five different panels including known and candidate genes were used to screen 105 patients with distinct PID features divided in three main PID categories: *T cell defects*, *Humoral defects* and *Other PIDs*. The Ion Torrent sequencing platform was used in 73 patients. Among these, 18 selected patients without a molecular diagnosis and 32 additional patients were analyzed by Haloplex enrichment technology.

Results: The complementary use of the two custom-made targeted sequencing approaches allowed the identification of causative variants in 28.6% ($n = 30$) of patients. Twenty-two out of 73 (34.6%) patients were diagnosed by Ion Torrent. In this group 20 were included in the SCID/CID category. Eight out of 50 (16%) patients were diagnosed by Haloplex workflow. Ion Torrent method was highly successful for those cases with well-defined phenotypes for immunological and clinical presentation. The Haloplex approach was able to diagnose 4 SCID/CID patients and 4 additional patients with complex and extended phenotypes, embracing all three PID categories in which this approach was more efficient. Both technologies showed good gene coverage.

Conclusions: NGS technology represents a powerful approach in the complex field of rare disorders but its different application should be weighted. A relatively small NGS target panel can be successfully applied for a robust diagnostic suspicion, while when the spectrum of clinical phenotypes overlaps more than one PID an in-depth NGS analysis is required, including also whole exome/genome sequencing to identify the causative gene.

Keywords: primary immunodeficiencies, Next Generation Sequencing, gene panels, Ion Torrent, Haloplex

INTRODUCTION

Primary immunodeficiencies (PIDs) are a phenotypically and genetically heterogeneous group of more than 300 monogenic inherited disorders resulting in immune defects that predispose patients to infections, autoimmune disorders, lymphoproliferative disease, and malignancies (1–3). PIDs with a more severe phenotype lead to life-threatening infections and life-limiting complications that require a prompt and accurate diagnosis in order to initiate lifesaving therapy (4, 5). Phenotypic and genotypic heterogeneity of PIDs make genetic diagnosis often complex and delayed. Indeed, more than one genotype might cause similar clinical phenotypes, but identical genotypes will not often produce the same phenotype and finally clinical penetrance may be different (6–9). The characterization of PID-associated genes is expected to significantly contribute to define the molecular events governing immune system development and will provide new insights into the pathogenesis of PIDs. Molecular genetic testing is also a useful tool for the diagnosis of PIDs in atypical cases (6, 10).

Despite the progress in the genetic characterization of PIDs, many patients still lack a molecular diagnosis. A better understanding of the genetic and immune defects of patients is critical to develop therapeutic strategies aimed at changing the clinical course of the disease and to guarantee an appropriate genetic counseling allowing the identification of PID patients before the onset of the disease (11–13). The application of Next Generation Sequencing (NGS) to PIDs has been a revolution and it has accelerated the discovery and identification of novel disease-causing genes and the genetic diagnosis of patients with monogenic inborn errors of immunity (7, 8, 14–16). Targeted gene-panel sequencing (17–21), whole exome sequencing (WES) (22, 23) or whole genome sequencing (WGS) (24) approaches can rapidly identify candidate gene variants in an increasing number of genetically undefined diseases (17, 24) and are widely used in several laboratories for the diagnosis of PIDs (10). WGS also offers the opportunity to find causative variants in the structural regions of a given gene. These tools increase the amount of data analysis that can identify causative genes in both clinically defined and atypical diseases. Nonetheless, delay in diagnosis can be caused by the huge amount of data retrieved from whole sequencing, increased costs sustained by clinical laboratories and the requirement of trained personnel to validate variants (7, 8, 22). An increased depth of the sequencing coverage is generally obtained using targeted gene panels, in favor of a high accuracy, amelioration of sensitivity and management of datasets, reducing the time of analysis, the costs and the interpretation of results, thus accelerating the diagnosis for the majority of PIDs (14, 16–18). On the other hand, the usefulness of targeted exome

Abbreviations: AD, Autosomal Dominant; AR, Autosomal Recessive; CAF, Common Allele Frequency; CDS, Coding Sequence; CID, Combined Immunodeficiencies; CVID, Common Variable Immunodeficiency; IGV, Integrative Genome Viewer; MAF, Minor Allele Frequency; NGS, Next Generation Sequencing; PCR, Polymerase Chain Reaction; PID, Primary Immunodeficiency; SCID, Severe Combined Immunodeficiency; SNP, Single Nucleotide Polymorphism; UTR, Untranslated Region; VCF, Variant Calling Format; WES, Whole Exome Sequencing; WGS, Whole Genome Sequencing.

sequencing approach for the identification of PID patients has been demonstrated, with accurate detection of point mutations and exonic deletions in patients with either known or unknown genetic diagnosis (7, 8).

In this study, we report the clinical and molecular characterization of 105 PID patients presenting with either typical SCID/CID or with overlapping PID phenotypes. Differently from other studies (20, 21, 25), most patients enrolled in this work had non-consanguineous parents. Two targeted sequencing approaches were compared to test the ion torrent reliability in diagnostics and Haloplex Target Enrichment System in diagnostics and for research purposes. **Three** diagnostic panels including known disease genes had been developed for the Ion Torrent platform (ThermoFisher). The Haloplex panels comprised well-defined PID genes (>300) and candidate genes associated with PIDs due to their expression and function in critical immune-pathways (1, 3). This work underlines how targeted NGS panels allow a high-throughput low-cost pipeline to identify the molecular bases of PIDs and are sensitive and accurate diagnostic tools for simultaneous mutation screening of known or putative PID-related genes.

MATERIALS AND METHODS

Patients

We report the clinical and molecular characterization of 105 PID patients mainly referred to three centers (2 in Rome and 1 in Milan) participating in the Italian network of PIDs (IPINET) and part of The European Reference Network on immunodeficiency, autoinflammatory, and autoimmune diseases (ERN RITA). Nine of these patients have been enrolled in the pCID study (DRKS00000497). Data were obtained from year 2014 to 2017.

Ion Torrent and/or Haloplex panels were applied for the analysis of samples and compared. Six patients previously diagnosed by Sanger sequencing were included in the study (**Table 2A**) as internal positive controls. The Ion Torrent panels were used for the analysis of 73 patients with suspicion of PID. Among this group, 18 patients, still remaining without a molecular diagnosis and 32 additional patients, were tested by Haloplex panels (Target Enrichment System for Illumina platform). The work was conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent, approved by the Ethical Committee of the Children's Hospital Bambino Gesù, San Raffaele Hospital (TIGET06, TIGET09) and Policlinico Tor Vergata, was obtained from either patients or their parents/legal guardians, if minors. Patients and their clinical and immunological features are reported in **Table 1**.

Ion Torrent Target System

Panel Design

The construction of targeted panels design required the study of several reported clinical phenotypes of known PID genes described in the IUIS (International Union of Immunological Societies) in the years 2014–2015. Our three custom Ion

Torrent panels were designed with Ampliseq Designer software using GRCh37 (panel 1 and 2) and GRCh38 (panel 3) as references. Primers were divided into two pools. The first custom panel (panel 1) contains 17 known genes related to SCID-CID phenotypes (85.85 kb). The second custom panel (panel 2) includes 24 genes for less frequent CID phenotypes (101.9 kb) and the third panel (panel 3) includes 62 genes for CVID (240.01 kb) (**Supplementary Tables S1–S3**). The final design was expected to cover 95.43% of the first panel, 94.13% of the second panel and 97.2% of the third genes panel. For each gene included in the panels a 10 bp of exon padding was included to cover the flanking regions of exon's coding sequences (CDS) including (panel 1 and 2) or not (panel 3) the untranslated regions (UTRs).

Ion Torrent Gene Target Library Preparation and NGS Sequencing

DNA was extracted by QIAamp DNA Blood Mini Kit (Qiagen). Five nanograms of gDNA were used for library preparation. DNA was amplified with 17 amplification cycles using gene panel Primer Pools and AmpliSeq HiFi mix (Thermo Fisher). PCR pools for each sample were combined and subjected to primer digestion with FuPa reagent (Thermo Fisher). Libraries were indexed using the Ion Xpress Barcode Adapter Kit. After purification, the amplified libraries were quantified with Qubit® 2.0 Fluorometer. All samples were diluted at a final concentration of 100 pM, then amplicon libraries were pooled for emulsion PCR (ePCR) on an Ion OneTouch System 2TM using the Ion PGM Template OT2 200 kit or Ion Chef according to manufacturer's instructions. Quality control of all libraries was performed on Qubit® 2.0 Fluorometer. Ampliseq Design Samples were subjected to the standard ion PGM 200 Sequencing v2 protocol using Ion 316 v2 chips or Ion S5 using Ion 520 v2 chips (Life Technologies).

Ion Torrent Bioinformatics Analysis, Variants Filtering, and Assessment of Pathogenicity

Mapping and variants calling were performed using the Ion Torrent suite software v3.6. Sequencing reads were aligned on GRCh37 (panel 1 and 2) and GRCh38 (panel 3) reference genome using the program distributed within the Torrent mapping Alignment Program (TMAP) map4 algorithm (Thermo Fisher; <https://github.com/Ion-Torrent/TS>). The alignment step is limited only to the regions of target genes. BAM files with aligned reads were processed for variant calling by Torrent Suite Variant Caller TVC program and variants in Variant Calling Format (VCF) file were annotated with ANNOVAR. Called variants with minimum coverage of 30X, standard Mapping Quality and Base Phred Quality were examined on Integrative Genome Viewer (IGV) and BIOMART. Filtering procedures selected variants with a minor allele frequency (MAF) <2% annotated using the following public databases: 1000 Genomes Project (2500 samples; <http://www.1000genomes.org/>), the Exome Variant Server (ESP) (6500 WES samples; <http://evs.gs.washington.edu/EVS/>) and the Exome Aggregation Consortium (ExAC) (60,706 samples; <http://exac.broadinstitute.org/>). Nonsense, frame-shift, start lost, stop lost,

TABLE 1 | Clinical, immunological and molecular features of PID patients.

PID ID	AGE AT PRESENTATION	GENDER	ADMITTING CLINICAL DIAGNOSIS	NGS PLATFORM	GENETIC DIAGNOSIS	NEUTRAL VARIANTS AND VUS	OPPORTUNISTIC/RECURRENT INFECTIONS	IMMUNITYREGULATION/MALIGNANCIES/ OTHERS	IMMUNOPHENOTYPE
PID 1	BIRTH	M	OMENN SYNDROME	ION TORRENT PANEL 1	RAG1		CHRONIC CMV VIREMIA, PNEUMOCYSTOSIS, HERPETIC KERATITIS	TUBULE INTERSTITIAL NEPHRITIS WITH LYMPHO-MONOCYTE INFILTRATE	T ⁺ , B ⁺ , NK ⁺
PID 2	2 mo	M	SCID	ION TORRENT PANEL 1	RAG2		EBV AND ADENOVIRUS POST HSCT		T ⁺ (↓CD4 ⁺ , ↓CD8), B ⁺ , ↑NK, ↓IgM, ↓IgA
PID 3	5 mo	F	SCID	ION TORRENT PANEL 1	RAG2		ADENOVIRUS		T ⁺ , B ⁺ , NK ⁺
PID 4	2mo	M	SCID	ION TORRENT PANEL 1	RAG1		CHRONIC CMV VIREMIA		T ⁺ , B ⁺ , NK ⁺ , ↓IgM
PID 5	5mo	M	SCID	ION TORRENT PANEL 1	IL2RG		ADENOVIRUS, HEPATITIS, ENTEROBACTER CLOACAE; CANDIDA	DERMATITIS (BOLLOUS TYPE)	T ⁺ , B ⁺ , ↑NK
PID 6	4mo	M	SCID	ION TORRENT PANEL 1	JAK3		INTERSTITIAL PNEUMONIA, PNEUMOCYSTOSIS		T ⁺ , B ⁺ , NK ⁺ , HYPOGAMMAGLOBULINEMIA
PID 7	4mo	M	SCID	ION TORRENT PANEL 1-2			INTERSTITIAL LUNG DISEASE; URI; LRI	HEPATOSPLENOMEGALY, AIHA, ITP	T ⁺ (ABSENT NAIVE and RTE, ↑γδ), B ⁺ , NK ⁺
PID 8	1 y	M	SCID	ION TORRENT PANEL 1-2				HEPATOSPLENOMEGALY, AIHA, ITP, VERTEBRAL WEDGING AND OSTEOPENIA	T (ABSENT NAIVE and RTE, ↑γδ), B ⁺ (↑UNSWITCHED MEMORY), NK ⁺
PID 9	9mo	F	SCID	ION TORRENT PANEL 1-2			GLUTEAL ABSCESS	CHRONIC DIARRHEA	T ⁺ (↑CM CD4 ⁺ , ↑γδ) B ⁺ , NK ⁻
PID 10	2mo	F	SCID	ION TORRENT PANEL 1-2			POST-NATAL CMV INFECTION; URI;LRI; NEONATAL SEPSIS		T ⁺ , B (ABSENT SWITCHED MEMORY), NK ⁺
PID 11	na	F	SCID	ION TORRENT PANEL 1-2			CHRONIC VZV VIREMIA	THROMBOCYTOPENIA	T ⁻ (↓ CD4), B ⁺ , NK ⁺
PID 12	1y	M	SCID	ION TORRENT PANEL 1-2/ HALOPLEX PANEL 2	ADA		URI		T ⁺ , B ⁺ , NK ⁺
PID 13	2y	M	SCID	ION TORRENT PANEL 1-2/ HALOPLEX PANEL 2		CECR1	PENUMONIA; CANDIDIASIS	GASTROENTERITIS, HyperIgE; LYELL SYNDROME, CARDIAC ARREST OF UNKNOWN ORIGIN; ILEOILEAL INTUSSUSCEPTION	LOW T, B ⁺ , ↑NK ⁺ , ↑IgM, ↓IgA, ↑IgE
PID 14	5mo	M	SCID	ION TORRENT PANEL 1-2			CHRONIC CMV AND EBV VIREMIA		↓T (ABSENT NAIVE CD4 and CD8, ↑γδ), B ⁺ , ↑NK
PID 15	1y	F	SCID	ION TORRENT PANEL 1-2	ADA		LRI		T ⁺ , B ⁺ , NK ⁺ , ↓IgM
PID 16	8 mo	M	leaky SCID	ION TORRENT PANEL 1-2	IL2RG		CHRONIC CMV VIREMIA, SEVERE CMV INTERSTITIAL PNEUMONIA	PNEUMONIA, DERMATITIS, GROWTH FAILURE	T ⁺ / ⁻ , B ⁺ , NK ⁺
PID 17	1y	M	SCID	ION TORRENT PANEL 1	IL2RG		CHRONIC CMV VIREMIA, BRONCHIOLITIS, UTI, ROTAVIRUS ENTERITIS	HEPATOSPLENOMEGALY, HLH	↓T (ABSENT NAIVE CD4 and CD8), B ⁺ , NK ⁺
PID 18	4d (DIED)	M	SCID	ION TORRENT PANEL 1	IL2RG		CMV, PNEUMOCYSTIS JIROVECI PNEUMONIA		T ⁺ , B ⁺ , ↓NK
PID 19	5mo	M	SCID	ION TORRENT PANEL 1	IL2RG		STAPHYLOCOCCUS HAEMOLYTICUS; ASPERGILLUS, BCGITIS		T ⁺ , ↑B ⁺ , ↓NK ⁺ , ↓IgM, ↓IgA
PID 20	1.8y	F	SCID	ION TORRENT PANEL 1-2	RAG1		LTI	HEPATOSPLENOMEGALY	T ⁺ , B ⁺ , NK ⁺ , ↑IgG, ↓IgM, ↓IgA, ↓IgE
PID 21	1y	M	SCID	ION TORRENT PANEL 1-2	CD3D		RHINOVIRUS, MYCOBACTERIUM		T (↑NAIVE CD4, ABSENT CD8, ↑γδ), B ⁺ , NK ⁺
PID 22	1.3y	M	SCID	ION TORRENT PANEL 1	RAG1		LRI, ADENOVIRUS, ROTAVIRUS ENTERITIS, PSEUDOMONAS AERUGINOSA		T ⁺ , B ⁺ , NK ⁺ , ↓IgM, ↓IgA, ↓IgE
PID 23	11mo	F	SCID	ION TORRENT PANEL 1	JAK3		CHRONIC HHV-6 VIREMIA, CANDIDA ALBICANS, ROTAVIRUS, CORONAVIRUS 229E;		T ⁺ , B ⁺ , ↑NK, ↑IgG, ↓IgM, ↓IgA
PID 24	4mo	F	SCID	ION TORRENT PANEL 1	JAK3		LRI, CANDIDA ALBICANS, RHINOVIRUS		T ⁺ , B ⁺ , ↑NK, ↓IgE

(Continued)

TABLE 1 | Continued

PID ID	AGE AT PRESENTATION	GENDER	ADMITTING CLINICAL DIAGNOSIS	NGS PLATFORM	GENETIC DIAGNOSIS	NEUTRAL VARIANTS AND VUS	OPPORTUNISTIC/RECURRENT INFECTIONS	IMMUNEDYSREGULATION/MALIGNANCIES/OTHERS	IMMUNOPHENOTYPE
PID 25	na	M	SCID	HALOPLEX PANEL 1	IL7R		na	na	T ⁺ , B ⁺ , NK ⁺
PID 26	1y	M	CID	HALOPLEX PANEL 1				AIHA	T ⁺ , B ⁺ , NK ⁺ , IgM, IgA
PID 27	5	F	CID	ION TORRENT PANEL 1-2/ HALOPLEX PANEL 1			IR, EPIDERMODYPLASIA VERRUCIFORMIS (HPV+8 WARTS); URI	MILD MYELODYSPLASIA, SEVERE HEPATIC STEATOSIS	T (JNAIVE and JRTB), B ⁺ , NK ⁺
PID 28	3	F	CID	ION TORRENT PANEL 1-2/ HALOPLEX PANEL 1			CHRONIC EBV VIREMIA, URI, PNEUMONIA	ENTEROPATHY; CHRONIC-PANCREATITIS; ANA/ANCA+	T (JNAIVE), B ⁺ , NK ⁺
PID 29	1 y	M	CID	ION TORRENT PANEL 1	RAG1		CHRONIC CMV AND EBV VIREMIA, HAEMOPHILUS INFLUENZAE AND BOCAVIRUS RESPIRATORY INFECTION, LONG-LASTING ROTAVIRUS DIARRHEA	THROMBOCYTOPENIA, AIHA, SEVERE HEPATOSPLENOMEGALY, WITH LIVER FAILURE	↓T, B ⁺ , NK ⁺ , ↑IgE, ↑IgM, ↑IgG
PID 30	3	M	CID	ION TORRENT PANEL 1-2			URI	DERMATITIS, ANA+	↓T (JNAIVE CD4), B ⁺ , NK ⁺
PID 31	3	F	CID	ION TORRENT PANEL 1	RAG1		CHRONIC HHV-6, CMV/EBV VIREMIA; URI, LRI	AIHA	T ⁺ , ↓B, NK ⁺ , ↓IgM, IgA
PID 32	3y	F	CID	ION TORRENT PANEL 1-2/ HALOPLEX PANEL 1			CHRONIC EBV VIREMIA, URI	HODGKIN LYMPHOMA; ENTEROPATHY	T (JNAIVE), B ⁺ , NK ⁺
PID 33	10y	M	CID	ION TORRENT PANEL 2			CHRONIC EBV VIREMIA, URI-LRI	LYMPHADENOPATHY, URTICARIA, LONG-COURSE DIARRHEA /LYMPHATIC HYPERPLASIA	T ⁺ , B ⁺ , NK ⁺
PID 34	1y	F	CID	ION TORRENT PANEL 1				SEVERE DERMATITIS, DIARRHEA, INTERSTITIOPATHY	T (↓CD8), ↑B ⁺ , NK ⁺
PID 35	11y	F	CID	HALOPLEX PANEL 1				COLITIS, GH DEFICIENCY	LYMPHOPEMIA, ↓T, ↓B, ↓NK (UNDER AZA)
PID 36	15 mo	F	CID	ION TORRENT PANEL 1-2	IL7R		CHRONIC EBV VIREMIA, URI (recurrent)	THROMBOCYTOPENIA, SEVERE DERMATITIS, GROWTH RETARDATION,	HYPERGAMMAGLOBULINEMIA (maternal engraftment)
PID 37	1mo	M	CID	HALOPLEX PANEL 2	ARPC1B		WARTS, RECURRENT INFECTIONS	VASCULITIS, LYMPHADENOPATHY, ECZEMA, HYPOGAMMAGLOBULINEMIA, HYPER IgE, THROMBOCYTOPENIA, LUNG DISEASE, BRONCHIECTASIS	↓T, B ⁺ , ↓NK, ↓IgG, ↓IgM, ↑IgA, ↑IgE
PID 38	0.8y	M	CID	HALOPLEX PANEL 2		NFKB1	RECURRENT ESOPHAGEAL CANDIDIASIS, LUNG ABSCESS	ESOPHAGEAL ATRESIA	T ⁺ , B ⁺ , NK ⁺
PID 39	13 mo	F	CID	HALOPLEX PANEL 1	RAG1		RECURRENT BRONCHITIS	SEVERE AUTOIMMUNE HEMOLYTIC ANEMIA, INTERSTITIAL PNEUMOPATHY AND BRONCHIECTASIS	T ⁺ , B ⁺ , NK ⁺
PID 40	na (adopted 11y)	F	CID	HALOPLEX PANEL 1			RECURRENT HERPETIC INFECTIONS (STOMATITIS)		↓T, ↓B, NK ⁺
PID 41	18 mo	F	CID	HALOPLEX PANEL 1			RECURRENT RESPIRATORY INFECTIONS AND OTITIS, POSITIVE HCV	HODGKIN LYMPHOMA, OBSTRUCTIVE LUNG DISEASE	↓T (↓CD4), B ⁺ , ↑IgM, ↓IgG, IgA
PID 42	1d	F	SYNDROMIC T-CELL DEFECT	ION TORRENT PANEL 1-2/ HALOPLEX PANEL 1			POST SURGICAL SEPSIS	CHDs, OSTEOMYELITIS	T ⁺ , B ⁺ , NK ⁺
PID 43	8y	M	SYNDROMIC T-CELL DEFECT	ION TORRENT PANEL 1-2			URI, NEONATAL SEPSIS	ATOPY, CHDs	T ⁺ , B ⁺ , NK ⁺
PID 44	4y	M	SYNDROMIC T-CELL DEFECT	ION TORRENT 1-2/ HALOPLEX PANEL 1			URI; SINUSITIS	MALFORMATIVE SYNDROME; PSYCHOMOTOR RETARDATION	T ⁺ , ↓B, NK ⁺
PID 45	13y	M	UNCLASSIFIED T-CELL DEFICIENCY	ION TORRENT PANEL 2/HALOPLEX PANEL 2			CHRONIC EBV VIREMIA, PNEUMONIA	HEPATOSPLENOMEGALY, LYMPHADENOPATHY; NEPHROTIC SYNDROME	T (JNAIVE CD4, CD8, RTE), ↓B, NK ⁺ , ↑IgM, IgA

(Continued)

TABLE 1 | Continued

PID ID	AGE AT PRESENTATION	GENDER	ADMITTING CLINICAL DIAGNOSIS	NGS PLATFORM	GENETIC DIAGNOSIS	NEUTRAL VARIANTS AND VUS	OPPORTUNISTIC/RECURRENT INFECTIONS	IMMUNITY/REGULATION/MALIGNANCIES/ OTHERS	IMMUNOPHENOTYPE
PID 66	3mo	F	CVID	ION TORRENT PANEL 1-2-3			URI; LRI; SEPSI	CANDIDA ENTERITIS, MALFORMATIVE SYNDROME, PSYCHOMOTOR RETARDATION, CHDs; CGH ARRAY: 15q25.1 DUPLICATION	T+, (TEMRA CD4), B+, NK+, IgM, IgA
PID 67	15y	M	CVID	HALOPLEX PANEL 1			SALMONELLA OSTEOMYELITIS	LINFADENOPATHY, SPLENOMEGALY, AHA, ITP	T+, B+, NK+, HYPOGAMMAGLOBULINEMIA
PID 68	6y	M	CVID	HALOPLEX PANEL 2				LINFADENOPATHY, SPLENOMEGALY, AHA, ITP, PULMONARY INFILTRATES, BRONCHIECTASIS	T+, B+, NK+, IgA-, IgG-
PID 69	1y	M	CVID	HALOPLEX PANEL 2			RECURRENT VZV, RECURRENT INFECTIONS	URTICARIA, ANGIOEDEMA, LUNG FIBROSIS	T+, B+, NK+, IgA ↓, IgG ↓
PID 70	15y	M	CVID	HALOPLEX PANEL 2		<i>TNFRSF13B</i>	RECURRENT INFECTIONS	LINFADENOPATHY, SPLENOMEGALY, HYPOTHYROIDISM, LUNG NODULAR INFILTRATES, GROUND GLASS	T+, B+, NK+, IgM ↓
PID 71	12y	F	CVID	HALOPLEX PANEL 2			RECURRENT PNEUMONIA	PULMONARY NODULES	T+, B+, NK+, HIPER IgG
PID 72	13y	M	CVID	HALOPLEX PANEL 1			SEPSI; URI, LRI	GASTROENTERITIS; HEPATOSPLENOMEGALY	T+, B+, NK+, IgG-, IgM-, IgA- (↑γδ), B+ ↓ MEMORY, NK+, IgM
PID 73	10y	M	SELECTIVE IgM DEFICIENCY	ION TORRENT PANEL 1-2-3				BRONCHIAL GRANULOMA	T+, (CD4), B+, ↓NK+, ↓IgA
PID 74	12y	F	HYPERIGG4	HALOPLEX PANEL 2		<i>TCF3</i>	ATYPICAL MYCOBACTERIOSIS (MAVUM)	DERMATITIS	T+ (↑NAIVE CD4, ↑LATE EFFETOR CD8, ↓THF, ↓TREG) B+ (↓MEMORY, ↑TRANSITIONAL), NK+
PID 75	2y	M	UNCLASSIFIED ANTIBODY IMMUNODEFICIENCY	ION TORRENT PANEL 1-2-3			CHRONIC HHV-6 VIREMIA, URI; PNEUMONIA; MOLLUSCUM CONTAGIOSUM		T+ (LOW NAIVE CD8), B+ (LOW MEMORY), IgM, ↓IgG, ↓IgA
PID 76	5y	M	UNCLASSIFIED ANTIBODY IMMUNODEFICIENCY	ION TORRENT PANEL 1-3/HALOPLEX PANEL 2		<i>MOD2</i>	CHRONIC CMV AND HHV-6 VIREMIA	BURKITT LYMPHOMA, EBV-REACTIVATION, CMV PRIMARY INFECTION	T+, B+ (↓ IgM MEMORY AND ↓SWITCHED MEMORY), NK+, IgM, ↓IgA
PID 77	6y	F	UNCLASSIFIED ANTIBODY IMMUNODEFICIENCY	ION TORRENT PANEL 1-2-3/HALOPLEX PANEL 2			CHRONIC EBV VIREMIA	THROMBOCYTOPENIA IMMUNOMEDATED, CELIAC DISEASE	T+, B+, NK+, ↓IgA
PID 78	12y	M	UNCLASSIFIED ANTIBODY IMMUNODEFICIENCY	ION TORRENT PANEL 1-2-3/HALOPLEX PANEL 2				DERMATITIS, FEMORAL DYSPLASIA	T+ (↑NAIVE CD4), B+ (↓ MEMORY), NK+
PID 79	3y	M	UNCLASSIFIED SYNDROMIC DEFICIENCY	ION TORRENT PANEL 1-2-3				ALOPECIA; ONYCHODYSTROPHY	T+, ↓B+, NK+, ↓IgG, ↓IgA
PID 80	6y	F	IMMUNE DYSREGULATION	ION TORRENT PANEL 1		<i>AIRE⁺ + PLCG2</i>	URI, LRI, RECURRENT SKIN INFECTIONS	INGUINAL ABSCESS; GRANULOMATOUS LYMPHADENITIS	T+ B+ NK+
PID 81	10y	M	IMMUNE DYSREGULATION	ION TORRENT PANEL 1-3/HALOPLEX PANEL 2			CHRONIC EBV, HHV-6, CMV VIREMIA, URI; UTI; PBI	APHTOSIS	T+, B+ (↓ IgM MEMORY and ↓SWITCHED MEMORY), NK+, IgA
PID 82	2y	F	INNATE IMMUNE DISEASE	ION TORRENT PANEL 1-2/HALOPLEX PANEL 1	<i>MYD88/ CARD9 JAGN1</i>		CHRONIC EBV VIREMIA, LRI, URI		T+, B+, NK+, NEUTROPENIA
PID 83	3y	M	NEUTROPENIA	HALOPLEX PANEL 2				SEVERE NEUTROPENIA	T+, B+, NK+, NEUTROPENIA
PID 84	1y	F	NEUTROPENIA	HALOPLEX PANEL 2	<i>CECR1</i>		RECURRENT INFECTIONS	CARDIOPATHY; NEUTROPENIA, NEUROLOGICAL DELAY, LIGAMENT LAXITY	T+ (↑CD4 CM, ↑RTE, ↑CD8 EM and TEMRA), B+ (↓SWITCHED MEMORY), NK+
PID 85	5y	F	NEUTROPENIA	HALOPLEX PANEL 2					
PID 86	13d	M	ALPS-LIKE	HALOPLEX PANEL 1	<i>NRAS</i>		URI	THROMBOCYTOPENIA; SPLENOMEGALY	

(Continued)

TABLE 1 | Continued

PID ID	AGE AT PRESENTATION	GENDER	ADMITTING CLINICAL DIAGNOSIS	NGS PLATFORM	GENETIC DIAGNOSIS	NEUTRAL VARIANTS AND VUS	OPPORTUNISTIC/RECURRENT INFECTIONS	IMMUNEDYSREGULATION/MALIGNANCIES/ OTHERS	IMMUNOPHENOTYPE
PID 87	3y	M	ALPS	HALOPLEX PANEL 2		<i>TNFRSF13B</i>	GENITAL AND PERIANAL WARTS, TONSILLITIS, PNEUMONIA	AHA, ITP, LINFOADENOPATHY, SPLENOmegALY, HYPOGAMGLOBULINEMIA, PULMONARY INFILTRATES ENTEROPATHY	T+, B+, NK+, IgG, IgM+, IgA
PID 88	8y	M	VEO-IBD	ION TORRENT PANEL 1	XIAP		CHRONIC EBV AND HHV-6 VIREMIA, URI		T+, B- (tCD8 EM and tEMRA), NK+
PID 89	4y	M	VEO-IBD	ION TORRENT PANEL 1			CHRONIC EBV VIREMIA	ENTEROPATHY; CELIAC SPRUE	↓T+, ↑B+, NK+
PID 90	2y	M	VEO-IBD	ION TORRENT PANEL 1-2/HALOPLEX PANEL 2			CHRONIC VZV VIREMIA, URI	CHRONIC DIARRHEA, CELIAC SPRUE	T+ (tNAIVE CD4) B+ NK+
PID 91	2mo	M	AUTOINFLAMMATORY SYNDROME	ION TORRENT PANEL 1-2			HLH; HEPATOSPLENOMEGALY; SKIN RASH; SYSTEMIC INFLAMMATORY SYNDROME	CHRONIC DIARRHEA, MONOCYTOPENIA	T+ (tCM CD4+ ↓ RTE), B+ (tSWITCHED MEMORY B CELL, tPLASMABLAST tCD21LOW, ↓TRANSITIONAL B CELL), AND DC-
PID 92	13y	F	AUTOINFLAMMATORY SYNDROME	HALOPLEX PANEL 2				SLE	T+, B+, NK+
PID 93	5y	F	UNCLASSIFIED SYNDROMIC DEFICIENCY	ION TORRENT PANEL 1-2			CHRONIC EBV VIREMIA, URI, PNEUMONIA	CHRONIC BRONCHOPNEUMOPATHY, MALFORMATIVE SYNDROME PSYCHOMOTOR DELAY	T+ (tCM CD4+ tTHF), B+ (↓ IgM MEMORY and tSWITCHED MEMORY), ↓ NK
PID 94	1y	M	UNCLASSIFIED SYNDROMIC DEFICIENCY	ION TORRENT PANEL 1-2			CHRONIC EBV VIREMIA	LAMBERT EATON SYNDROME, GLIOMA, 5q- MYELODISPLASIA; PSYCHOMOTOR RETARDATION; POLYNEUROPATHY	T+ ↓B NK+
PID 95	1.5y	M	UNCLASSIFIED SYNDROMIC DEFICIENCY	HALOPLEX PANEL 1		<i>BMP4</i>	URI, LRI	THROMBOCYTOPENIA, HYPERLAXITY, DENTAL ANOMALIES; DYSMORPHIC FEATURES; CRYPTORCHIDISM; SEVERE MYOPIA; ECTODERMAL DYSPLASIA SIGNS	T+, B+, NK+
PID 96	9y	M	SYNDROMIC	ION TORRENT PANEL 1-2			URI, POLYALLERGY	INTERSTITIAL TUBULOPATHY; CHRONIC PANCREATITIS; CHRONIC GASTRODUODENITIS; MILD ESOPHAGITIS; BRONCHOPNEUMOPATHY WITH BRONCHIECTASIAS.	T+ (tCM CD4+ ↓ RTE), B+, NK+
PID 97	4y	M	SYNDROMIC	ION TORRENT PANEL 1				HYPOSUPPRESSED; COATS DISEASE; MYELODYSPLASIA; HYPOSPADIAS; MONOSOMY CHR 7 GROWTH RETARDATION, IUGR	T+ (t CD4+), B+, ↓NK+
PID 98	2y	M	ACUTE LIVER FAILURE	ION TORRENT PANEL 1-2			CHRONIC EBV VIREMIA, TWO EPISODES OF ACUTE EPATITIS	FOOD ALLERGY	T+ (tγδ), B+, NK+
PID 99	4y	M	HYPERSENSITIVITY	ION TORRENT PANEL 1			LTI (RECURRENT BRONCHITIS), ORAL PAPULOMATOSIS, ATOPIC DERMATITIS		
PID 100	16y	F	IMMUNEDYSREGULATION	HALOPLEX PANEL 1			RECURRENT INFECTIONS	ENTEROCOLITIS	T+, B+, NK+
PID 101	7y	F	IMMUNE DYSREGULATION	HALOPLEX PANEL 2			WARTS, NAIL FUNGAL INFECTION (NOT RECURRENT)	ALOPECIA, AUTOIMMUNE THYROIDITIS, MILD LYMPHOPENIA	↓T, B+, NK+
PID 102	na	M	OTHER (TROMBOCYTOPENIC PURPURA)	ION TORRENT PANEL 1-2				HYPOSPADIAS, ITP	T+ (tCM CD4+), B+, NK+
PID 103	11y	M	OTHER	HALOPLEX PANEL 2				ALOPECIA	T+, B+, NK+
PID 104	13y	M	OTHER	HALOPLEX PANEL 2				ITP	T+, B+, NK+, IgG, ↓IgA
PID 105	4y	F	OTHER	HALOPLEX PANEL 2				AUTOIMMUNE/AUTOINFLAMMATORY PHENOTYPE	

EBV, Epstein-Barr; CMV, Cytomegalovirus; VZV, Varicella-Zoster Virus; HHV-6, Human Papilloma Virus; URI, Upper Respiratory Infection; LRI, Lower Respiratory Infection; UTI, Urinary Tract Infection; SLE, Systemic Lupus Erythematosus; ITP, Idiopathic Thrombocytopenic Purpura; HLH, Hemophagocytic Lymphohistiocytosis; ALHA, Autoimmune Haemolytic Anemia; CHDs, Congenital Heart Disease; NF1, Neurofibromatosis 1. ↓ low as compared to age matched normal range; ↑high as compared to age matched normal range.

Black Bold: Ion Torrent diagnosis. Blue Bold: Haloplex diagnosis. Different colors show genes in which we found: Violet* > Previous Sanger detections in predisposing gene variants to PID; Violet > predisposing gene variants to PID. Gray > no-causative disease variants; Green > variants of uncertain significance (VUS); Orange > variant in genes partially associated to the clinical phenotype.

TABLE 2A | Genetic mutations in 6 positive control PID patients.

ID	Disease	Gene	RefSeq	Mutation		dbSNP and references	Zygosity	Method	OMIM
PID I	OS	<i>RAG1</i>	NM_000448	a) c.1682G>A; p.R561H	b) c.1871G>A; p.R624H	rs104894284; rs199474680	Compound Heterozygous	Ion Torrent	OMIM *179615
PID II	SCID	<i>IL2RG</i>	NM_000206	a) c.452T>C; p.L151P		rs137852511	Hemizygous	Ion Torrent	OMIM *308380
PID III	SCID	<i>JAK3</i>	NM_000215	a) c.1208G>A; p.R403H		Scarselli et al. (35)	Homozygous	Ion Torrent	OMIM *600173
PID IV	SCID	<i>LIG4</i>	NM_001352601	a) c.833G>A, p.R278H	b) c.1271_1275delAAAGA; p.K424RfsTer20	Cifaldi et al. (36)	Compound Heterozygous	Ion Torrent	OMIM *601837
PID V	leaky SCID	<i>RAG1</i>	NM_000448	a) c.2521C>T; p.R841W		rs104894287	Homozygous	Ion Torrent	OMIM *179615
PID VI	leaky SCID	<i>RAG1</i>	NM_000448	a) c.256_257del; p.K86VfsTer33		rs772962160	Homozygous	Ion Torrent	OMIM *179615

In bold novel mutations.

and canonical splice site variants were considered potentially pathogenic (6). *In silico* prediction of functional consequences of novel SNV was performed using Mutation taster, LTR, Polyphen2, SIFT, and CADD score >15 (26–30) and literature available data. **Supplementary Figure 1A** summarizes all steps of the process.

Haloplex Target System Panel Design

We designed *two* panels including up to 300 known PID genes (3) chosen from a Custom Gene Target Panel from Agilent SureDesign online tool (http://web16.kazusa.or.jp/rapid_original/) and about 300 candidate additional genes taken from the RAPID web site (<http://rapid.rcai.riken.jp>) from the RIKEN Center for Integrative Medical Science, from the literature and the ESID Online Registry. The candidate genes category includes genes that might be found in clinically relevant PID pathways and can share similar biological function of known PID genes. The first panel of 623 target genes comprised 7,245 regions with 66,600 amplicons, while the second panel of 601 target genes, included 6,984 regions and 73,061 amplicons. The designed probes capture 25 flanking bases in the coding exons regions (**Supplementary Tables 4A,B**). The final probe design was expected to cover >97% of target regions. Practical coverage is indicated.

Haloplex Gene Target Library Preparation and NGS Sequencing

Genomic DNA was extracted by QIAamp DNA Blood Mini Kit (Qiagen) and quantified by Qubit dsDNA BR Assay Kit (ThermoFisher). DNA integrity was checked by agarose gel (1% of agarose in TAE 1x). Genomic DNA was enriched with Haloplex Target Enrichment System kit (Agilent Technologies Inc., 2013, Waghäusel-Wiesental, Germany). Libraries were prepared according to the manufacturer's instructions. Briefly, 225 ng of genomic DNA was enzymatically digested; fragments were hybridized with conjugated biotin probes for 16 h at 54°C. Circularized target DNA-Haloplex probe hybrids were captured

with streptavidin-coated magnetic beads. DNA ligase was added to the capture reaction to close nicks in the circularized probe-target DNA hybrids. All DNA samples were individually indexed during the hybridization step and library PCR amplification was performed on the Mastercycler Nexus Thermal Cyclers (Life Sciences Biotechnology, Hamburg, Germany). Amplicons were purified with AMPure XP beads (Beckman Coulter, Inc., Krefeld, Germany). Sequencing was performed with a MiSeq Reagent Kit v3 (600 Cycles) with 7 pM of sample libraries loaded on the Illumina MiSeq (San Diego, CA, USA). Quality controls after fragmentation and final concentration of prepared libraries, were assessed by Bioanalyzer (Agilent Technologies Inc., Eindhoven, the Netherlands).

Haloplex Bioinformatics Analysis, Variants Filtering, and Assessment of Pathogenicity

FastQ files were aligned to the human reference genome (UCSC hg19, GRCh37) by Burrows–Wheeler Aligner (31). Picard HsMetrics was applied to analyze the target-capture sequencing experiments (<http://picard.sourceforge.net/>) and internal scripts were used to calculate mean gene coverage. Variant calling was performed by FreeBayes (32). Raw variants were filtered by the following parameters: QUAL > 1, (QUAL/AO) > 10, SAF > 0, SAR > 0, RPR > 1, RPL > 1. Variants with an allele depth below 20 reads were excluded from the analysis. Selected variants were annotated for dbSNP-146, ClinVar, dbNSFP v2.9 databases and SnpEff (33) and were filtered for Common Allele Frequencies (CAF) <5% and variant effect on exons (missense, frameshift, splice acceptor/donor, start lost, stop lost, stop gained, 3'UTR, 5'UTR). Variants found in the either 5' or 3' UTR were excluded from the subsequent analyses. *In silico* analysis for variants' pathogenicity was determined according to 5 prediction tools: Mutation taster, LTR, Polyphen2, SIFT, and CADD score >15 (26–30). In case of trios, variants were subdivided according to model of inheritance (Autosomal Recessive/Dominant, X-linked, *De novo*). The complete bioinformatics analysis is reported in **Supplementary Figure 1B**.

Statistical Analysis

Data were analyzed with Graph-Pad Prism, version 6.2 (Graph Pad Software, la Jolla, CA).

RESULTS

Characterization of PID Patients

In this study, we report the clinical and molecular characterization of 105 PID patients presenting with either typical or overlapping PID phenotypes. Patients were clustered according to initial clinical presentation in 3 main categories (**Figure 1A**): *T-cell defects* (including Omenn syndrome, SCID, CID, syndromic T-cell defect, unclassified T-cell deficiency, hyper IgM syndrome); *Humoral defects* (agammaglobulinemia, CVID, unclassified antibody deficiency, dysgammaglobulinemia); *Other PIDs* (immune dysregulation, innate immunity defects

including congenital defects of phagocytes, syndromic defects with immune-deficiency signs/symptoms, ALPS-ALPS-like, autoinflammatory syndrome, and a miscellaneous that includes non-typical PID patients with a broad range of clinical phenotypes). The clinical, immunological, and molecular features are reported in **Table 1**. The percentage of patients in each subgroup is shown in **Figures 1B–D**. Among the *T-cell defects* ($n = 50$; 47.7%), the majority of patients presented with SCID (48%), followed by CID (32%) (**Figure 1B**). The *Humoral Defects* group ($n = 28$; 26.6%) was mainly represented by CVID (75%), while the *Other PIDs* group ($n = 27$; 25.7%) included a wide spectrum of rare defects and uncommon phenotypes.

Seventy-three PID patients were analyzed by Ion Torrent sequencing system using three different panels including SCID/CID and CVID known genes. Two Haloplex panels including more than 600 known and candidate PID genes




FIGURE 1 | Clinical diagnosis of patients at admission. **(A)** Percentage of patients for three main categories. Percentage of each clinical diagnosis in patients belonging to **(B)** *T cell defects*, **(C)** *Humoral defects* and **(D)** *Other PIDs* categories. For each category the total number of patients is indicated.

were applied to 32 additional patients. Additionally, 18 patients previously analyzed by Ion Torrent but still without a clear molecular diagnosis, were analyzed by Haloplex system. A flow chart showing the *route map* for sequencing of index patients is shown in **Figure 2**.


Target Enrichment Performance and Gene Coverage


The mean target coverage resulted of $529 \pm 169X$ (panel 1), $361 \pm 97X$ (panel 2) and $417 \pm 117X$ (panel 3) for Ion Torrent and $229 \pm 25X$ for Haloplex panels (**Supplementary Figure 2A**). The mean target coverage for Ion Torrent panels was optimal as compared to recently published works in which a coverage of 335X was obtained (34). Indeed, the Ion Torrent expected coverage of the coding regions was 95.43% for panel 1 (SCID-CID), 94.13% for panel 2 (rare CID) and 97.2% for the panel 3 (**Supplementary Tables 1–3**). The practical coverage obtained from Ion Torrent panels is shown in **Supplementary Figures 2B–D**.

Primer design for Haloplex aimed at covering more than 97% of the coding regions for all genes. The observed coverage of the targeted regions after running the two panels is represented in **Supplementary Tables 4A,B**. The majority of shared genes included in all panels and analyzed by both technologies were well-covered (**Supplementary Figures 3A–C**).

Performance Evaluation

The use of large panels for NGS retrieved a big number of data as compared to small panels. Putative variants detected by Ion Torrent have been examined and validated obtaining an average of false positive variants $<0.6\%$. Such value decreases reducing the number of genes included in the panel. Haloplex produces larger amount of variants, but only the ones significantly indicative among those related to the patient's phenotype have been investigated; hence, we could not properly evaluate data accuracy. In the 18 patients resequenced by Haloplex, no variants in genes included in the Ion Torrent panels were found supporting the accuracy of these methods. Furthermore,





6 available samples previously diagnosed by Sanger sequencing with 8 known different mutations in *RAG1*, *IL2RG*, *JAK3*, and *LIG4* genes, were included in the study and detected by Ion Torrent panel 1 (Table 2A).

One false negative diagnosis has been recently recognized. Indeed, the Torrent Suite Variant Caller TVC program was unable to identify the c.C664T: p.R222C mutation in exon 5 of *IL2RG* gene in patient PID16 but this was detectable on IGV.

Molecular Diagnoses

In our cohort, 28.6% (30/105) of molecular diagnosis was obtained (Figure 3A). Sanger sequencing for all mutations and parents' carrier status were performed. Functional studies were conducted for most novel variants and results are reported in Table 2B.

A rapid molecular diagnosis was established in 30.1% (22/73) of PID patients who were investigated by Ion Torrent. Diagnoses were achieved in *RAG1*, *RAG2*, *IL2RG*, *JAK3*, *ADA*, *CD3D*,

IL7R, *CD40L*, and *XIAP* genes (see Table 2B). As expected, the identification of a molecular defect resulted more frequent in patients with a clear clinical and immunological phenotype as shown in those included in the group of *T cell defects* (20/42; 47.6%) (Figure 3B). Interestingly, the percentage of diagnosis in the group of SCID/CID patients was 60.6% (20/33).

The percentage of molecular diagnosis for the 50 patients studied through the Haloplex panels was of 16% (8/50) as shown in Figure 3A. The first 6 diagnoses were obtained in a cohort of 32 patients. Three SCID/CID patients with mutations in *RAG1*, *IL7R* and *ARPC1B* genes [(40, 45–47) and Volpi et al., under revision] were diagnosed in 8 *T cell defects* (37.5%). Moreover, *JAGN1* (48), *CECR1* (43) and *NRAS* genes, associated to complex phenotypes, were identified in 12 of the *Other PIDs* group (25%) (Figure 3C).

Two additional patients were diagnosed analyzing the 18 patients, previously negative by Ion Torrent, presenting with a less defined immunological phenotype (Figure 3D). For one patient (PID12), the Ion Torrent panel 1 was able to detect

TABLE 2B | Mutations detected in our PID cohort.

ID	Disease	Gene	RefSeq	Mutation	dbSNP and references	Zygosity	Inheritance	Method	OMIM	Functional test
PID 1	OS	<i>RAG1</i>	NM_000448	a) c.1870C>T; p.R624C	rs199474688; rs104894287	Compound	Familial	Ion Torrent	OMIM *179615	
PID 2	SCID	<i>RAG2</i>	NM_000536	a) c.685G>T; p.R229W		Heterozygous				
PID 3	SCID	<i>RAG2</i>	NM_000536	a) c.1A>G; p.M1V	rs765298019	Homozygous	Unknown	Ion Torrent	OMIM *179616	n.a.
				b) c.1403_1406del ATCT	n.d.; rs786205616	Compound	Familial	Ion Torrent	OMIM *179616	
PID 4	SCID	<i>RAG1</i>	NM_000448	a) c.1681C>T; p.R561C	rs104894285; Dobbs et al. (37)	Heterozygous	Familial	Ion Torrent	OMIM *179615	Recombinase activity ongoing
PID 5	SCID	<i>IL2RG</i>	NM_000206	a) c.202G>A; p.E68K	rs.1057520644	Heterozygous	Familial	Ion Torrent	OMIM *308380	
PID 6	SCID	<i>JAK3</i>	NM_000215	a) c.1796T>G; p.V599G	Di Matteo et al. (38); rs748216175	Compound	Familial	Ion Torrent	OMIM *600173	Published data
PID 12	SCID	<i>ADA</i>	NM_000022	a) c.455T>C p.L152P	n.d.; Santisteban et al. (39)	Compound	Familial	Ion Torrent/Haloplex	OMIM *608958	Reduced ADA enzymatic activity
PID 15	SCID	<i>ADA</i>	NM_000022	a) c.367delG; p.D123fsTer10	n.d.	Heterozygous	Familial	Ion Torrent	OMIM *608958	Reduced ADA enzymatic activity
PID 16	CID	<i>IL2RG</i>	NM_000206	a) c.C664T; p.R222C	rs111033618	Homizygous	De novo	Ion Torrent	OMIM *308380	
PID 17	SCID	<i>IL2RG</i>	NM_000206	a) c.677G>A; p.R226H	rs869320660	Homizygous	Familial	Ion Torrent	OMIM *308380	
PID 18	SCID	<i>IL2RG</i>	NM_000206	a) c.854G>A; (splice)	rs111033617	Homizygous	Familial	Ion Torrent	OMIM *308380	
PID 19	SCID	<i>IL2RG</i>	NM_000206	a) c.455T>G; p.V152G	n.d.	Homizygous	Familial	Ion Torrent	OMIM *308380	n.a.
PID 20	SCID	<i>RAG1</i>	NM_000448	a) c.1229G>A; p.R410Q	rs199474684; n.d.	Compound	Unknown	Ion Torrent	OMIM *609889	n.a.
PID 21	SCID	<i>CD3D</i>	NM_000732	a) c.274+5G>A	rs730880296	Heterozygous		Ion Torrent	OMIM *186790	
PID 22	SCID	<i>RAG1</i>	NM_000448	a) c.987delC; p.S330LfsTer15	n.d.	Homizygous	Mother, n.a.	Ion Torrent	OMIM *179615	Evident pathogenicity
PID 23	SCID	<i>JAK3</i>	NM_000215	a) c.308G>A; p.R103H	rs774202259	Homizygous	Unknown	Ion Torrent	OMIM *600173	
PID 24	SCID	<i>JAK3</i>	NM_000215	a) c.1132G>C; p.G378R	rs1485406844; JAK3base_D0095	Compound	Familial	Ion Torrent	OMIM *600173	
PID 25	SCID	<i>IL7R</i>	NM_002185	a) c.134A>C; p.Q45P	n.d.; rs777878144	Heterozygous	Familial	Haloplex	OMIM *146661	n.a.
PID 29	CID	<i>RAG1</i>	NM_000448	a) c.2521C>T; p.R841W	rs104894287	Compound	Familial	Ion Torrent	OMIM *179615	
PID 31	CID	<i>RAG1</i>	NM_000448	a) c.1871G>A; p.R624H	rs199474680; n.d.	Compound	Familial	Ion Torrent	OMIM *179615	Recombinase activity ongoing
PID 36	CID	<i>IL7R</i>	NM_002185	a) c.160T>C; p.S54P	rs1002396899; rs757797163	Heterozygous	Familial	Ion Torrent	OMIM *146661	
PID 37	CID	<i>ARPC1B</i>	NM_005720	a) c.64+1G>A	Brigida et al. (40) (accepted)	Heterozygous	Familial	Haloplex	OMIM *604223	Published data
PID 39	CID	<i>RAG1</i>	NM_000448	a) c.2119G>C; p.E665D	n.d.; rs1241698978	Compound	Unknown	Haloplex	OMIM *179615	n.a.

(Continued)

TABLE 2B | Continued

ID	Disease	Gene	RefSeq	Mutation	dbSNP and references	Zygosity	Inheritance	Method	OMIM	Functional test
PID 49	HIGM	CD40LG	NM_000074	a) c.410-2 A>T	rs1254732497	Hemizygous	Familial	Ion Torrent	OMIM *300386	
PID 51	CVID	RAG1	NM_000448	a) c.1871G>A; p.R624H	rs199474680; Cifaldi et al. (41)	Compound Heterozygous	Familial	Ion Torrent	OMIM *179615	Published data
PID 88	IBD	XIAP	NM_001167	a) c.566T>C; p.L189P	Cifaldi et al. (42)	Hemizygous	De novo	Ion Torrent	OMIM *300079	Published data
PID 83	NEUTROPENIA	JAGN1	NM_032492	a) c.63G>T; p.E21D	rs587777729	Homozygous	Familial	Haloplex	OMIM *616012	
PID 84	NEUTROPENIA	CECR1	NM_001282225	a) c.1367A>G; p.Y456C	Barzaghi et al. (43)	Compound Heterozygous	Familial	Haloplex	OMIM *607575	Accepted for publication
PID 82	INNATE IMMUNE DISEASE	CARD9	NM_052813	a) c.1434+1G>C	rs141992399	Homozygous	Familial	Ion Torrent/Haloplex	OMIM *607212	
		MYD88	NM_002468	a) c.195_197delGGA; p.E66del	rs878852993	Homozygous	Familial		OMIM *602170	
PID 86	ALPS-LIKE	NRAS	NM_002524	a) c.35G>A; p.G12D	rs121913237	Heterozygous	Somatic	Haloplex	OMIM *164790	

In bold novel not described mutations

only a missense mutation in the *ADA* gene. Haloplex identified the second intronic mutation located in the fifth nucleotide upstream exon 5, not included in the Ion Torrent design, of the gene. In the second Ion Torrent negative patient (PID82) presenting an atypical HyperIgE syndrome, Haloplex detected two rare homozygous mutations in *MYD88* and *CARD9* genes, which were not included in the Ion Torrent panels (1 and 2). The pathogenic role of each single gene mutation is still under investigation but this molecular information is important to optimize the clinical management of the patient including the evaluation of HSCT as definitive treatment (44).

In summary, 4 SCID/CID patients out of a total of 16 *T cell defects*, were identified by Haloplex, demonstrating once more a higher percentage of diagnosis in this PID group (Table 2B). However, although the possibility to identify a causative gene mutation correlates with a precise clinical clusterization, the identification of patients, with complex and extended phenotypes, needs larger NGS panels.

Disease-Associated Variants

Comparing the results obtained by the two methods, 44 (32 Ion Torrent and 12 Haloplex) disease-associated variants have been identified in 30 patients, of whom 18 were novel (Table 2B). The majority of variants detected by Ion Torrent were missense ($n = 23$; 74.2%) as summarized in Figure 4A. We were also able to detect 4 small deletions and 5 splice site variants. The Haloplex panels detected 5 missense, 2 deletions, 4 splice site and 1 stop codon variants (Figure 4B). Among the 30 diagnosed patients, we found 13 compound heterozygous patients with mutations in *RAG1*, *JAK3*, *ADA*, *IL7R*, and *CECR1* genes, 9 homozygous variants including *ADA*, *RAG1*, *RAG2*, *CD3D*, *JAK3*, *ARPC1B*, *MYD88/CARD9*, and *JAGN1*, 7 hemizygous variants in *IL2RG*, *CD40LG*, and *XIAP*, and only 1 heterozygous somatic variant in *NRAS* (Figure 4C). Therefore, most patients enrolled in this study were offspring of non-consanguineous marriages. The most frequent mutated gene in our cohort is *RAG1* followed by *IL2RG* (Figure 4D).

Putative Neutral Variants vs. Variants of Uncertain Significance (VUS)

Fifteen CVID patients were initially analyzed by Ion Torrent panels 1-2, but no causative variants were found. We therefore designed a specific CVID panel and found 4 putative causative variants suggestive of AD disease that was confirmed by Sanger sequencing. Indeed, we found a heterozygous damaging variant in the *CTLA4* gene and a predicted damaging variant in the *PTEN* gene in an adult patient followed since childhood (PID56). The patient inherited one mutation from the father and one from the mother but the real role of these variants and their possible combined effect is still under investigation. In addition, two other VUS in *TCF3* and *PLCG2* genes were found in two patients (PID75 and PID54), in which no other evidences are available (see Table 1).

A rare variant in *CD40L* gene (p.R200S) found in patient PID50 was excluded from the analysis, although an altered CD40L expression was detected. This variant was predicted




FIGURE 4 | Type and zygosity of mutations and mutated genes distribution. Types and percentage of mutations found in diagnosed PID patients for Ion Torrent **(A)** and Haloplex **(B)**. **(C)** Overall observed zygosity for diagnosed PID patients. **(D)** Total number of detected mutated genes.

benign in multiple databases. Furthermore, a homozygous rare variant in *CECR1* gene (p.Q233R) was found in patient PID13. However, the two proband's healthy brothers were found to be homozygous for this variant thus it was not considered pathogenic, nevertheless, additional functional studies will be performed to exclude genetic predisposition (e.g., ADA2 activity, protein expression).

Three novel variants of uncertain significance (VUS) identified by Haloplex in patients with classical and complex phenotypes are still “under investigation.” We are currently validating a novel damaging variant in the *TCF3* gene in two twin patients (PID57-58) and their mother affected by CVID (49). EMSA assay is ongoing to assess the capacity of TCF3 protein to bind DNA target sequences. In these twin patients we also previously found by Sanger sequencing a mutation in *TNFRSF13B* gene already described to be associated to CVID (50).

A causative variant in the *BMP4* gene (51) with a severe myopia, ectodermal dysplasia, and cytopenia was found in a patient (PID95) in whom the altered immunological phenotype remains poorly explained by this mutation. Moreover, *NFKB1* variant in a CID patient (PID38) was found but its significance is still under investigation.

Finally, heterozygous variants in *TNFRSF13B* (PID70, PID87) and *NOD2* (PID77), genes were found by Haloplex in three patients. Generally, variants in susceptibility genes involved in the disease pathogenesis should be considered for potential future phenotypic implications particularly in adult patients where multiple factors may contribute to the onset of the disease.

DISCUSSION

The application of multigene NGS panels has extended our knowledge of PIDs and is currently recognized as a

comprehensive diagnostic method in the field of rare disorders consenting the diagnosis in the 15–70% of all cases depending on the PID clinical and phenotypic clusterization (25, 52). In the present work we show that the complementary, integrated use of two custom-made targeted sequencing approaches, Ion Torrent or Haloplex, allowed to clearly identify causative variants in 28.6% ($n = 30$) of the patients in all groups of PIDs, confirming the value of NGS assays to obtain a genetic diagnosis for PIDs (17–23).

The Ion Torrent approach resulted highly successful for SCID patients, a group generally more defined for its immunological and clinical presentation (53). Indeed, with this approach we identified 20/33 SCID/CID patients (60,6%). The Haloplex workflow was able to identify causative variants in 8/50 patients (16%) of whom 4 were found in the group of SCID/CID patients and 4 fall in that of complex and extended phenotypes. Interestingly, a molecular diagnosis was achieved in 2/18 (11%) patients presenting with typical and atypical clinical phenotypes resulted negative after Ion Torrent analysis and included in the Haloplex approach.

By NGS it is possible to identify unexpected mutations in apparently not corresponding PID cases, as recently reported by our group for a patient with agammaglobulinemia due to *RAG1* deficiency (41). This result strengthen the notion of a large phenotypic variety associated with RAG deficiency, suggesting that it should be considered also in patients presenting with an isolated marked B-cell defect (54–57) and as already reported that RAG mutations are more frequent than expected. Notably, RAG1 is the most frequent PID cause in our cohort. This case represents a paradigmatic model of how new questions arise on the management and follow-up for patients in which a milder phenotype could be associated to alternative treatments to transplantation (41, 57, 58).

CVID is a typical example of a disease with a broad phenotype due to different gene alterations (59–61). Notably, in 4 CVID patients with mutations in *TNFRSF13B* and *AIRE* previously detected by Sanger sequencing (see **Table 1**) we extended NGS analysis to looking for novel disease causing genes. Therefore, frequent variants comparable to polymorphisms should be considered with caution since the pathogenic meaning is still unclear. Additional functional studies in these cases are required. Four additional diagnoses are summarized in **Supplementary Table 5** (62). These were obtained after the completion of the present study by other targeted NGS panels and Sanger sequencing, indicating that the combination of in-depth clinical knowledge and appropriate sequencing techniques can lead to new diagnoses.

Although the prioritization methods applied in this study follows all common assumptions for a correct data analysis, the identification of novel variants currently under investigation represents a challenge and their validation needs the essential support of further in-depth experimental studies (6–8, 63). The integration of clinical, immunological, biochemical and molecular data might favor a revised PIDs classification of patients with similar phenotype due to a different genetic cause, or patients with different phenotypes but with the same genetic cause. In our experience, the

use of selected NGS panels is useful and easy to handle for rapid diagnosis in clinically and immunologically well-characterized phenotypes. As compared to WES, targeted small NGS panels provide an important alternative for clinicians for direct sequencing of relevant genes, guaranteeing a high coverage and sequencing depth (64). On the contrary, their application in patients with atypical phenotypes could result in an incomplete and delayed diagnosis. Extended gene panels or WES should be directly used in these cases for research purposes, to allow the diagnosis of unexpected genotype-phenotype association.

As reported by several groups (7, 8, 22–24), the application of targeted WES for each suspicion of PID by exploring gene-by-gene also for limited numbers of striking genes still remain time and resource consuming in the absence of synergy between clinical and bioinformatics supports. This is yet unfeasible for extended diagnostic purposes. Indeed, the huge amount of retrieved data and the risk of incidental findings in other non-PID genes involved in different monogenic or multifactorial pathologies may be confounding and do not corresponding to the first suspicion. Additionally, the confidence of the results decreases with the number of targeted genes and may preclude any variant detection in self-evident known genes (65). Many previously undetected variants do not have a well-defined role in our genome (1.5×10^6 million variants in each genome and lesser in exome). In this scenario, ethical and legal issues related to the disclosure of genetic information generated by NGS need to be considered and guidelines should be developed to help the different specialists to translate the genetic results into the clinics (64).

The achievement of NGS application will require further integration of knowledge based on clinical, immunological and molecular data and the collaboration among different experts in these fields. A better clinical, immunological and genetic characterization of new PIDs will significantly contribute to the identification of diagnostic and prognostic markers and early individual therapeutic strategies with significant patients' benefit.

DATA AVAILABILITY

Data have been uploaded to ClinVar, accession number: SUB5252744.

AUTHOR CONTRIBUTIONS

CrC, IB, and GD performed experiments, developed gene panels for targeted sequencing. CrC, IB, FB, and DMG interpreted the results and wrote the manuscript. DP, CrC, VF, FS, CaC, and GD created gene clusters to filter variants and integrated clinical and bioinformatics analysis of data retrieved by Ion Torrent platform. IB, DL, DC, FB, MPC, MZ, DP, CrC, GD, MO, and CaC created gene clusters to filter variants and integrated clinical and bioinformatics analysis of data retrieved by Haloplex workflow. CrC, IB, SD, GF, MC, MZ, MG, AV, and GD performed

molecular and functional experiments. FB, MPC, EA, FC, AS, FL, FF, CP, GF, GB, PM, DM, ClC, PP, SC, AT, VM, LC, CA, AF, FLi, PR, CaC, and AA provided or referred clinical samples and patient's clinical data. GD, IB, SG, FS, CrC, CaC, and AA participate to the study design and data interpretation. CaC, FS, GD, and AA designed the research, participate to the study design and data interpretation. FS, VM, SG, SF, and FLi made substantial contributions to revising the manuscript. CaC, GD, and AA supervised the research and manuscript revision. Legend: CrC, Cifaldi Cristina; FC, Conti Francesca; CaC, Cancrini Caterina; ClC, Canessa Clementina; FL, Licciardi Francesco; FLi, Locatelli Franco.

FUNDING

The study was supported by grants of the Italian Ministero della Salute (NET-2011-02350069) to AA and CaC, the European Commission (ERARE-3-JTC 2015 EUROCID) to AA, the Ricerca Corrente from Children's Hospital Bambino Gesù, Rome, Italy (201702P003966) to CaC, Fondazione Telethon (GGP15109) to AF and Fondazione Telethon (TIGET Core grant C6) to AA. MPC and GF acknowledge 5x1000 OSR PILOT & SEED GRANT by Ospedale San Raffaele. IB received fellowship from not-for-profit LaSpes organization. MZ, FB, and DP conducted this study as partial fulfillment of their Ph.D. in Immunology, Molecular Medicine, and Applied Biotechnologies Applicate, Tor Vergata University, Rome, Italy. Participating centers are part of the Italian Network for Primary Immunodeficiencies (IPINET) of Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP).

REFERENCES

- Bousfiha A, Jeddane L, Picard C, Ailal F. The 2017 IUIS phenotypic classification for primary immunodeficiencies. *J Clin Immunol.* (2018) 38:129–43. doi: 10.1007/s10875-017-0465-8
- Notarangelo LD. Primary immunodeficiencies. *J Allergy Clin Immunol.* (2010) 125:S182–94. doi: 10.1016/j.jaci.2009.07.053
- Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, et al. International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. *J Clin Immunol.* (2018) 38:96–128. doi: 10.1007/s10875-017-0464-9
- Ochs HD, Hagin D. Primary immunodeficiency disorders: general classification, new molecular insights, and practical approach to diagnosis and treatment. *Ann Allergy Asthma Immunol.* (2014) 112:489–95. doi: 10.1016/j.anai.2014.04.007
- Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. *J Allergy Clin Immunol.* (2015) 136:1186–205. doi: 10.1016/j.jaci.2015.04.049
- Casanova J-L, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. *J Exp Med.* (2014) 211:2137–49. doi: 10.1084/jem.20140520
- Meyts I, Bosch B, Bolze A, Boisson B, Itan Y. Exome and genome sequencing for inborn errors of immunity. *J Allergy Clin Immunol.* (2016) 138:957–69. doi: 10.1016/j.jaci.2016.08.003
- Seleman M, Hoyos-Bachiloglu R, Geha RS, Chou J. Uses of next-generation sequencing technologies for the diagnosis of primary immunodeficiencies. *Front Immunol.* (2017) 8:847. doi: 10.3389/fimmu.2017.00847
- Erman B, Bilic I, Hirschmugl T, Salzer E, Boztug H, Sanal, et al. Investigation of Genetic Defects in Severe Combined Immunodeficiency Patients from Turkey by targeted sequencing. *Scand J Immunol.* (2017) 85:227–34. doi: 10.1111/sji.12523
- Heimall JR, Hagin D, Hajjar J, Henrickson SE, Hernandez-Trujillo HS, Tan Y, et al. Use of genetic testing for primary immunodeficiency patients. *J Clin Immunol.* (2018) 38:320–9. doi: 10.1007/s10875-018-0489-8
- Lenardo M, Lo B, Lucas CL. Genomics of immune diseases and new therapies. *Annu Rev Immunol.* (2016) 34:121–49. doi: 10.1146/annurev-immunol-041015-055620
- Notarangelo LD, Fleisher TA. Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders. *J Allergy Clin Immunol.* (2017) 139:715–23. doi: 10.1016/j.jaci.2017.01.004
- Valencic E, Grasso AG, Conversano E, Lucafo M, Piscianz E, Gregori M, et al. Theophylline as a precision therapy in a young girl with PIK3R1 immunodeficiency. *J Allergy Clin Immunol Pract.* (2018) 6:2165–7. doi: 10.1016/j.jaip.2018.02.029
- Raje N, Soden S, Swanson D, Ciaccio CE, Kingsmore SF, Dinwiddie DL. Utility of Next Generation Sequencing in Clinical Primary Immunodeficiencies. *Curr Allergy Asthma Rep.* (2014) 14:1–13. doi: 10.1007/s11882-014-0468-y
- Picard C, Fischer A. Contribution of high-throughput DNA sequencing to the study of primary immunodeficiencies. *Eur J Immunol.* (2014) 44:2854–61. doi: 10.1002/eji.201444669
- Suzuki T, Sasahara Y, Kikuchi A, Kakuta H, Kashiwabara T, Ishige T, et al. Targeted sequencing and immunological analysis reveal the involvement of primary immunodeficiency genes in pediatric IBD: a Japanese Multicenter Study. *J Clin Immunol.* (2017) 37:67–79. doi: 10.1007/s10875-016-0339-5

ACKNOWLEDGMENTS

The authors are grateful to Dr. Taruscio and Dr. Torrerì (Istituto Superiore di Sanità) for their help in the development of patient's database. The authors are grateful to patients and families.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2019.00316/full#supplementary-material>

Supplementary Figure 1 | Schematic representation of filtering variants strategy for Ion Torrent **(A)** and Haloplex **(B)**.

Supplementary Figure 2 | Coverage analysis. **(A)** Mean target coverage for genes included in Haloplex and Ion Torrent panels 1–2 and 3. Box and whiskers show median, 5th and 95th percentiles. Haloplex shows 605 shared genes in the two panels. **(B)** Mean gene coverage for Ion Torrent Panel 1, **(C)** panel 2 and **(D)** panel 3. Coverage is shown as number of reads.

Supplementary Figure 3 | Comparison of coverage analysis. **(A–C)** Comparison of mean gene coverage in shared genes between Ion Torrent and Haloplex panels.

Supplementary Table 1 | Theoretical coverage of genes included in Ion Torrent panel 1.

Supplementary Table 2 | Theoretical coverage of genes included in Ion Torrent panel 2.

Supplementary Table 3 | Theoretical coverage of genes included in Ion Torrent panel 3.

Supplementary Table 4 | **(A)** Theoretical and effective coverage of gene intervals in Haloplex platform panel 1. **(B)** Theoretical and effective coverage of gene intervals in Haloplex platform panel 2.

Supplementary Table 5 | Additional diagnoses obtained after this study.

17. Stoddard JL, Niemela JE, Fleisher TA, Rosenzweig SD. Targeted NGS : a cost-effective approach to molecular diagnosis of PIDs. *Front Immunol.* (2014) 5:531. doi: 10.3389/fimmu.2014.00531
18. Moens LN, Falk-Sörqvist E, Asplund AC, Bernatowska E, Smith CIE, Nilsson M. Diagnostics of primary immunodeficiency diseases: a sequencing capture approach. *PLoS ONE.* (2014) 9:e114901. doi: 10.1371/journal.pone.0114901
19. Nijman IJ, Van Montfrans JM, Hoogstraat M, Boes ML, Van De Corput L, Renner ED, et al. Targeted next-generation sequencing: a novel diagnostic tool for primary immunodeficiencies. *J Allergy Clin Immunol.* (2014) 133:1–7. doi: 10.1016/j.jaci.2013.08.032
20. Fang M, Abolhassani H, Lim CK, Zhang J, Hammarström L. Next generation sequencing data analysis in primary immunodeficiency disorders – future directions. *J Clin Immunol.* (2016) 36:68–75. doi: 10.1007/s10875-016-0260-y
21. Al-Mousa H, Abouelhoda M, Monies DM, Al-Tassan N, Al-Ghoniaim A, Al-Saud B, et al. Unbiased targeted next-generation sequencing molecular approach for primary immunodeficiency diseases. *J Allergy Clin Immunol.* (2016) 137:1780–7. doi: 10.1016/j.jaci.2015.12.1310
22. Stray-Pedersen A, Sorte HS, Samarakoon P, Gambin T, Chinn IK, Coban Akdemir ZH, et al. Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. *J Allergy Clin Immunol.* (2017) 139:232–45. doi: 10.1016/j.jaci.2016.05.042
23. Gallo V, Dotta L, Giardino G, Cirillo E, Lougaris V, D'Assante R, et al. Diagnostics of primary immunodeficiencies through next-generation sequencing. *Front Immunol.* (2016) 7:466. doi: 10.3389/fimmu.2016.00466
24. Mousallem T, Urban TJ, McSweeney KM, Kleinstein SE, Zhu M, Adeli M, et al. Clinical application of whole-genome sequencing in patients with primary immunodeficiency. *J Allergy Clin Immunol.* (2015) 136:476–9.e6. doi: 10.1016/j.jaci.2015.02.040
25. Bisgin A, Boga I, Yilmaz M, Bingol G, Altintas D. The utility of next-generation sequencing for primary immunodeficiency disorders: experience from a clinical diagnostic laboratory. *Biomed Res Int.* (2018) 2018:9647253. doi: 10.1155/2018/9647253
26. Lubeck E, Coskun AF, Zhiyentayev T, Ahmad M, Cai L. MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods Nat Methods Nat Methods.* (2012) 9:743–8. doi: 10.1038/nmeth.2892
27. Chun S, Fay JC. Identification of deleterious mutations within three human genomes. *Genome Res.* (2009) 19:1553–61. doi: 10.1101/gr.092619.109.2001
28. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. *Curr Protoc Hum Genet.* (2013) Chapter 7:Unit7.20. doi: 10.1002/0471142905.hg0720s76
29. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc.* (2009) 4:1073–81. doi: 10.1038/nprot.2009.86
30. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet.* (2014) 46:310–5. doi: 10.1038/ng.2892
31. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv Prepr arXiv.* (2013).
32. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. *arXiv Prepr arXiv12073907.* (2012) 9.
33. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly.* (2012) 6:80–92. doi: 10.4161/fly.19695
34. Abolhassani H, Chou J, Bainter W, Platt CD, Tavassoli M, Momen T, et al. Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency. *J Allergy Clin Immunol.* (2018) 141:1450–8. doi: 10.1016/j.jaci.2017.06.049
35. Scarselli A, Di Cesare S, Di Matteo G, De Matteis A, Ariganello P, Romiti ML et al. Combined immunodeficiency due to JAK3 mutation in a child presenting with skin granuloma. *J Allergy Clin Immunol.* (2016) 137:948–51.e5. doi: 10.1016/j.jaci.2015.09.017
36. Cifaldi C, Angelino G, Chiriaco M, Di Cesare S, Claps A, Serafinelli J, et al. Late-onset combined immune deficiency due to LIGIV mutations in a 12-year-old patient. *Pediatr Allergy Immunol.* (2017) 28:203–6. doi: 10.1111/pai.12684
37. Dobbs K, Tabellini G, Calzoni E, Patrizi O, Martinez P, Giliani SC, et al. Natural killer cells from patients with recombina-activating gene and non-homologous end joining gene defects comprise a higher frequency of CD56bright NKG2A+ + + cells, and yet display increased degranulation and higher perforin content. *Front Immunol.* (2017) 8:1244. doi: 10.3389/fimmu.2017.01244
38. Di Matteo G, Chiriaco M, Scarselli A, Cifaldi C, Livadiotti S, Di Cesare S. JAK3 mutations in Italian patients affected by SCID: new molecular aspects of a long-known gene. *Mol Genet Genomic Med.* (2018) 6:713–21. doi: 10.1002/mgg3.391
39. Santisteban I, Arredondo-Vega FX, Kelly S, Mary A, Fischer A, Hummell DS, et al. Novel splicing, missense, and deletion mutations in seven adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency disease. Contribution of genotype to phenotype. *J Clin Invest.* (1993) 92:2291–302.
40. Brigida I, Zoccolillo M, Cicalese MP, Barzaghi F, Scala S, Oleaga-C, et al. T-cell defects in patients with ARPC1B germline mutations account for combined immunodeficiency. *Blood.* (2018) 132:2362–74. doi: 10.1182/blood-2018-07-863431
41. Cifaldi C, Scarselli A, Petricone D, Di Cesare S, Chiriaco M, Claps A, et al. Agammaglobulinemia associated to nasal polyposis due to a hypomorphic RAG1 mutation in a 12 years old boy. *Clin Immunol.* (2016) 173:121–3. doi: 10.1016/j.clim.2016.09.013
42. Cifaldi C, Chiriaco M, Di Matteo G, Di Cesare S, Alessia S, De Angelis P, et al. Novel X-linked inhibitor of apoptosis mutation in very early-onset inflammatory bowel disease child successfully treated with HLA-haploidentical hemopoietic stem cells transplant after removal of $\alpha\beta$ +T and B cells. *Front Immunol.* (2017) 8:1893. doi: 10.3389/fimmu.2017.01893
43. Barzaghi F, Minniti F, Mauro M, Bortoli M, Balter R, Bonetti E, et al. ALPS-like phenotype caused by ADA2 deficiency rescued by allogeneic hematopoietic stem cell transplantation. *Front Immunol.* (2019) 9:2767. doi: 10.3389/fimmu.2018.02767
44. Chiriaco M, Di Matteo G, Conti F, Petricone D, De Luca M, Di Cesare S, et al. First case of patient with two homozygous mutations in MYD88 and CARD9 genes presenting with pyogenic bacterial infections, elevated IgE, and persistent EBV viremia. *Front. Immunol.* (2019) 10:130. doi: 10.3389/fimmu.2019.00130
45. Kuijpers TW, Tool ATJ, van der Bijl I, de Boer M, van Houdt M, de Cuyper IM, et al. Combined immunodeficiency with severe inflammation and allergy caused by ARPC1B deficiency. *J Allergy Clin Immunol.* (2017) 140:273–77.e10. doi: 10.1016/j.jaci.2016.09.061
46. Kahr WHA, Pluthero FG, Elkadri A, Warner N, Drobac M, Chen CH, et al. Loss of the Arp2/3 complex component ARPC1B causes platelet abnormalities and predisposes to inflammatory disease. *Nat Commun.* (2017) 8:14816. doi: 10.1038/ncomms14816
47. Somech R, Lev A, Lee YN, Simon AJ, Barel O, Schiby G, et al. Disruption of thrombocyte and T lymphocyte development by a mutation in ARPC1B. *J Immunol.* (2017) 199:4036–45. doi: 10.4049/jimmunol.1700460
48. Cifaldi C, Sera J, Petricone D, Brigida I, Cesare S Di, Matteo G Di, et al. Next-generation sequencing reveals A JAGN1 mutation in a syndromic child with intermittent neutropenia. *J Pediatr Hematol Oncol.* (2018). doi: 10.1097/MPH.0000000000001256. [Epub ahead of print].
49. Engel I, Murre C. The function of E- and ID proteins in lymphocyte development. *Nat Rev Immunol.* (2001) 1:193–9. doi: 10.1038/35105060
50. Ameratunga R, Koopmans W, Woon S-T, Leung E, Lehnert K, Slade CA, et al. Epistatic interactions between mutations of TACI (TNFRSF13B) and TCF3 result in a severe primary immunodeficiency disorder and systemic lupus erythematosus. *Clin Transl Immunol.* (2017) 6:e159. doi: 10.1038/cti.2017.41
51. Huang Y, Lu Y, Mues G, Wang S, Bonds J, D'Souza R. Functional evaluation of a novel tooth agenesis-associated bone morphogenetic protein 4 prodomain mutation. *Eur J Oral Sci.* (2013) 121:313–8. d doi: 10.1111/eos.12055
52. Rae W, Ward D, Mattocks C, Pengelly RJ, Eren E, Patel SV, et al. Clinical efficacy of a next-generation sequencing gene panel for primary immunodeficiency diagnostics. *Clin Genet.* (2018) 93:647–55. doi: 10.1111/cge.13163

53. Yu H, Zhang VW, Stray-Pedersen A, Hanson IC, Forbes LR, de la Morena MT, et al. Rapid molecular diagnostics of severe primary immunodeficiency determined by using targeted next-generation sequencing. *J Allergy Clin Immunol.* (2016) 138:1142–51.e2. doi: 10.1016/j.jaci.2016.05.035
54. Abolhassani H, Wang N, Aghamohammadi A, Rezaei N, Lee YN, Frugoni F, et al. A hypomorphic recombination-activating gene 1 (RAG1) mutation resulting in a phenotype resembling common variable immunodeficiency. *J Allergy Clin Immunol.* (2014) 134:1375–80. doi: 10.1016/j.jaci.2014.04.042
55. Kato T, Crestani E, Kamae C, Honma K, Yokosuka T, Ikegawa T, et al. RAG1 Deficiency May Present Clinically as Selective IgA Deficiency. *J Clin Immunol.* (2015) 35:280–8. doi: 10.1007/s10875-015-0146-4
56. Hedayat M, Massaad MJ, Lee YN, Conley ME, Orange JS, Ohsumi TK, et al. Lessons in gene hunting: A RAG1 mutation presenting with agammaglobulinemia and absence of B cells. *J Allergy Clin Immunol.* (2014) 134:983–5. doi: 10.1016/j.jaci.2014.04.037
57. Notarangelo LD, Kim MS, Walter JE, Lee YN. Human RAG mutations: biochemistry and clinical implications. *Nat Rev Immunol.* (2016) 16:234–6. doi: 10.1038/nri.2016.28
58. Villa A, Sobacchi C, Notarangelo LD, Bozzi F, Abinun M, Abrahamsen TG, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. *Blood.* (2001) 97:81–8. doi: 10.1182/blood.V97.1.81
59. Bogaert DJA, Dullaers M, Lambrecht BN, Vermaelen KY, De Baere E, Haerynck F. Genes associated with common variable immunodeficiency: one diagnosis to rule them all? *J Med Genet.* (2016) 53:575–90. doi: 10.1136/jmedgenet-2015-103690
60. van Schouwenburg PA, Davenport EE, Kienzler AK, Marwah I, Wright B, Lucas M, et al. Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders. *Clin Immunol.* (2015) 160:301–4. doi: 10.1016/j.clim.2015.05.020
61. Maffucci P, Filion CA, Boisson B, Itan Y, Shang L, Casanova JL, et al. Genetic diagnosis using whole exome sequencing in common variable immunodeficiency. *Front Immunol.* (2016) 7:220. doi: 10.3389/fimmu.2016.00220
62. Caorsi R, Rusmini M, Volpi S, Chiesa S, Pastorino C, Sementa AR, et al. CD70 deficiency due to a novel mutation in a patient with severe chronic EBV infection presenting as a periodic fever. *Front Immunol.* (2018) 8:2015. doi: 10.3389/fimmu.2017.02015
63. Itan Y, Casanova J-L. Novel primary immunodeficiency candidate genes predicted by the human gene connectome. *Front Immunol.* (2015) 6:142. doi: 10.3389/fimmu.2015.00142
64. Roy S, Coldren C, Karunamurthy A, Kip NS, Klee EW, Lincoln SE, et al. Standards and guidelines for validating next-generation sequencing bioinformatics pipelines. *J Mol Diagn.* (2017) 20:4–27. doi: 10.1016/j.jmoldx.2017.11.003
65. Petersen BS, August D, Abt R, Alldafari M, Atarod L, Baris S, Bhavsar H, et al. Targeted gene panel sequencing for early-onset inflammatory bowel disease and chronic diarrhea. *Inflamm Bowel Dis.* (2017) 23:2109–20. doi: 10.1097/MIB.0000000000001235

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Cifaldi, Brigida, Barzaghi, Zoccolillo, Ferradini, Petricone, Cicalese, Lazarevic, Cittaro, Omrani, Attardi, Conti, Scarselli, Chiriaco, Di Cesare, Licciardi, Davide, Ferrua, Canessa, Pignata, Giliani, Ferrari, Foustari, Barera, Merli, Palma, Cesaro, Gattorno, Trizzino, Moschese, Chini, Villa, Azzari, Finocchi, Locatelli, Rossi, Sangiuolo, Aiuti, Cancrini and Di Matteo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.